$Sangamo Therapeutics (SGMO.US)$
This is the new medicine. Gene Therapies will save the heathcare systems of the world Trillions in the future.
Pfizer's Hemophilia B treatment already approved is just the beginning. GLTA.
"Internal CSL figures estimate that between annual bleed rates and required therapies to address hemophilia B, a patient with the disease can cost an insurer $20 million over the course of their life. That puts the expenditure of $3.5 million for a gene therapy to reverse or c...

$Oncolytics Biotech (ONCY.US)$
Earnings report and updates tomorrow morning before opening.  It's overdue. We're they waiting for something to announce?? GLTA.

$Sangamo Therapeutics (SGMO.US)$
Looking like it's coming together.
10 dollar target from HCW today. GLTA

$Sangamo Therapeutics (SGMO.US)$
Check this out....  Cost of ERT therapy for lifetime for a Fabry patient.  Dutch study. The numbers will surprise you!!!
https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-8-29

$Sangamo Therapeutics (SGMO.US)$
price consolidating.  some people taking profits.  Fabry deal when announced should  put us over $2 I think. Still holding full position at 0 .68  patiently holding for a big payday next year sometime I think.

$Sangamo Therapeutics (SGMO.US)$
Hope so. Big position here under $0.60
GLTA.

$Oncolytics Biotech (ONCY.US)$
Watch for results coming out of mFOLFIRINOX PELAREOREP and Roche’s Tecentriq.  We should get safety results on a few patients by EOY. If we get good tumor shrinkage like in last trial with GEM and PAX,  we should be off and running with two potential treatments for Pancreatic Cancer. 2025 might be our buyout year. GLTA.

$Oncolytics Biotech (ONCY.US)$
Pancreatic cancer data will be good,  just have to wait a bit more. Good results from mFOLFIRINOX safety trial hopefully before EOY.  GLTA.  All new analysts targets are higher and rated overweight.